Latest News in the pharma Industry

Policy & Regulation

Pfizer Announces FDA Acceptance For Review Of sNDA for Oral Xeljanz for Adult Patients With Moderate To Severe Chronic Plaque Psoriasis

Pfizer Announces FDA Acceptance For Review Of sNDA for Oral Xeljanz for Adult Patients With Moderate To Severe Chronic Plaque Psoriasis

5 Feb 2015

Read more 
Alcon Receives FDA Approval of Pazeo Solution for Ocular Allergy Itch Relief

Alcon Receives FDA Approval of Pazeo Solution for Ocular Allergy Itch Relief

2 Feb 2015

Read more 
FDA Approves Bristol-Myers Squibb’s Evotaz for the Treatment of HIV-1 Infection in Adults

FDA Approves Bristol-Myers Squibb’s Evotaz for the Treatment of HIV-1 Infection in Adults

30 Jan 2015

Read more 
Eylea Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to CRVO/BRVO

Eylea Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to CRVO/BRVO

29 Jan 2015

Read more 
Amgen Submits Applications in the US and Europe for Kyprolis (Carfilzomib) for the Treatment of Relapsed Multiple Myeloma

Amgen Submits Applications in the US and Europe for Kyprolis (Carfilzomib) for the Treatment of Relapsed Multiple Myeloma

29 Jan 2015

Read more 
Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic Sivextro

Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic Sivextro

27 Jan 2015

Read more 
pSivida Reports Iluvien Receives Marketing Authorization in Two More EU Countries

pSivida Reports Iluvien Receives Marketing Authorization in Two More EU Countries

27 Jan 2015

Read more 
Impax Receives FDA Approval for a Generic Version of Lamictal Orally Disintegrating Tablets

Impax Receives FDA Approval for a Generic Version of Lamictal Orally Disintegrating Tablets

26 Jan 2015

Read more 
NICE Recommends Xarelto (Rivaroxaban) as an Effective Treatment Option for Reducing Risk of Secondary Events in ACS

NICE Recommends Xarelto (Rivaroxaban) as an Effective Treatment Option for Reducing Risk of Secondary Events in ACS

23 Jan 2015

Read more 
21 CFR Part 11 Compliance for SaaS/Cloud Applications: 2-Day In-Person Seminar

21 CFR Part 11 Compliance for SaaS/Cloud Applications: 2-Day In-Person Seminar

20 Jan 2015

Read more 
Fresenius Kabi Receives FDA Approval for Neostigmine Methylsulfate Injection

Fresenius Kabi Receives FDA Approval for Neostigmine Methylsulfate Injection

20 Jan 2015

Read more 
Regeneron and Sanofi Announce Praluent Marketing Authorization Application has Been Accepted for Review by EMA

Regeneron and Sanofi Announce Praluent Marketing Authorization Application has Been Accepted for Review by EMA

15 Jan 2015

Read more